CD8A and hepatocellular carcinoma: Regorafenib, multiple kinase inhibitor, decreased tumor CD31-positive angiogenesis, the total number of TAMs, but increased M1/M2 ratio and infiltration of tumor by CD4+ and CD8+ T cell in mouse model of HCC [254].